Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells.

Surichan S, Androutsopoulos VP, Sifakis S, Koutala E, Tsatsakis A, Arroo RR, Boarder MR.

Food Chem Toxicol. 2012 Sep;50(9):3320-8. doi: 10.1016/j.fct.2012.06.030. Epub 2012 Jun 26.

PMID:
22743247
2.

Tangeretin and its metabolite 4'-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K.

Cheng Z, Surichan S, Ruparelia K, Arroo R, Boarder MR.

Br J Pharmacol. 2011 Apr;162(8):1781-91. doi: 10.1111/j.1476-5381.2010.01185.x.

3.

Endosomal signalling of epidermal growth factor receptors contributes to EGF-stimulated cell cycle progression in primary hepatocytes.

Luo Y, Cheng Z, Dixon CJ, Hall JF, Taylor E, Boarder MR.

Eur J Pharmacol. 2011 Mar 5;654(2):173-80. doi: 10.1016/j.ejphar.2010.11.038. Epub 2010 Dec 21.

PMID:
21172338
4.

Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats.

Sena CM, Nunes E, Louro T, Proença T, Fernandes R, Boarder MR, Seiça RM.

Br J Pharmacol. 2008 Mar;153(5):894-906. Epub 2007 Oct 1.

5.
6.

Regulation of human hepatocytes by P2Y receptors: control of glycogen phosphorylase, Ca2+, and mitogen-activated protein kinases.

Dixon CJ, White PJ, Hall JF, Kingston S, Boarder MR.

J Pharmacol Exp Ther. 2005 Jun;313(3):1305-13. Epub 2005 Mar 11.

PMID:
15764738
7.

Regulation of rat hepatocyte function by P2Y receptors: focus on control of glycogen phosphorylase and cyclic AMP by 2-methylthioadenosine 5'-diphosphate.

Dixon CJ, Hall JF, Webb TE, Boarder MR.

J Pharmacol Exp Ther. 2004 Oct;311(1):334-41. Epub 2004 May 19.

PMID:
15152027
8.

ATP and UTP responses of cultured rat aortic smooth muscle cells revisited: dominance of P2Y2 receptors.

Kumari R, Goh G, Ng LL, Boarder MR.

Br J Pharmacol. 2003 Dec;140(7):1169-76. Epub 2003 Nov 3.

9.

P2Y receptor regulation of cultured rat cerebral cortical cells: calcium responses and mRNA expression in neurons and glia.

Bennett GC, Ford AP, Smith JA, Emmett CJ, Webb TE, Boarder MR.

Br J Pharmacol. 2003 May;139(2):279-88.

10.
11.
12.

Isoform-specific inhibition of voltage-sensitive Ca(2+) channels by protein kinase C in adrenal chromaffin cells.

Sena CM, Santos RM, Standen NB, Boarder MR, Rosário LM.

FEBS Lett. 2001 Mar 9;492(1-2):146-50.

13.

Antiproliferative effect of UTP on human arterial and venous smooth muscle cells.

White PJ, Kumari R, Porter KE, London NJ, Ng LL, Boarder MR.

Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2735-42.

14.
15.

Regulation of cyclic AMP by extracellular ATP in cultured brain capillary endothelial cells.

Anwar Z, Albert JL, Gubby SE, Boyle JP, Roberts JA, Webb TE, Boarder MR.

Br J Pharmacol. 1999 Sep;128(2):465-71.

16.

Regulation of Ca2+ influx by a protein kinase C activator in chromaffin cells: differential role of P/Q- and L-type Ca2+ channels.

Sena CM, Santos RM, Boarder MR, Rosário LM.

Eur J Pharmacol. 1999 Feb 5;366(2-3):281-92.

PMID:
10082210
17.

Evidence that P2Y4 nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP.

Harper S, Webb TE, Charlton SJ, Ng LL, Boarder MR.

Br J Pharmacol. 1998 Jun;124(4):703-10.

18.

The regulation of vascular function by P2 receptors: multiple sites and multiple receptors.

Boarder MR, Hourani SM.

Trends Pharmacol Sci. 1998 Mar;19(3):99-107. Review.

PMID:
9584626
19.

Regulation of brain capillary endothelial cells by P2Y receptors coupled to Ca2+, phospholipase C and mitogen-activated protein kinase.

Albert JL, Boyle JP, Roberts JA, Challiss RA, Gubby SE, Boarder MR.

Br J Pharmacol. 1997 Nov;122(5):935-41.

21.
22.

P2 purinoceptor-stimulated conversion of arginine to citrulline in bovine endothelial cells is reduced by inhibition of protein kinase C.

Brown CA, Patel V, Wilkinson G, Boarder MR.

Biochem Pharmacol. 1996 Dec 24;52(12):1849-54.

PMID:
8951343
24.

Cloned and transfected P2Y4 receptors: characterization of a suramin and PPADS-insensitive response to UTP.

Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR.

Br J Pharmacol. 1996 Dec;119(7):1301-3.

26.
27.

PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.

Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR.

Br J Pharmacol. 1996 Jun;118(3):704-10.

29.
30.
31.

Stimulation of prostacyclin release by endothelial ATP receptors requires activation of protein kinase C and tyrosine kinases.

Brown CA, Bowden A, Patel V, Boarder MR.

Biochem Soc Trans. 1996 Feb;24(1):55S. No abstract available.

PMID:
8674729
32.
33.

PPADS: an antagonist at endothelial P2Y-purinoceptors but not P2U-purinoceptors.

Brown C, Tanna B, Boarder MR.

Br J Pharmacol. 1995 Nov;116(5):2413-6.

34.

Tyrosine phosphorylation, MAPK and PLD in AII stimulated mitogenesis.

Morton C, Wilkie N, Boarder MR.

Biochem Soc Trans. 1995 Aug;23(3):426S. No abstract available.

PMID:
8566314
35.

Stimulation of nitric oxide synthase by endothelial purinoceptors does not correlate with inositol trisphosphate levels.

Brown CA, Wilkinson GF, Boarder MR.

Biochem Soc Trans. 1995 Aug;23(3):425S. No abstract available.

PMID:
8566313
36.

Regulation of bradykinin responses by PKC epsilon and histamine responses by PKC alpha in adrenal chromaffin cells.

Boarder MR, Sena CM, Parker PJ, Patel V, Rosario LM.

Biochem Soc Trans. 1995 Aug;23(3):424S. No abstract available.

PMID:
8566312
37.

Binding of [35S]adenosine 5'-O-(2-thiodiphosphate) to endothelial cells in culture.

Wilkinson GF, Boarder MR.

Biochem Pharmacol. 1995 May 17;49(10):1411-8.

PMID:
7763284
38.
39.

G protein-coupled P2 purinoceptors: from molecular biology to functional responses.

Boarder MR, Weisman GA, Turner JT, Wilkinson GF.

Trends Pharmacol Sci. 1995 Apr;16(4):133-9. Review.

PMID:
7610499
40.

Measurement of diacylglycerol. Origins of receptor-stimulated diacylglycerol accumulation.

Boarder MR, Purkiss JR.

Methods Mol Biol. 1995;41:189-202. No abstract available.

PMID:
7655556
41.

Classification of P2 purinoceptors. Not all G protein-coupled P2 purinoceptors can be classed as P2Y.

Boarder MR, Turner JT, Erb L, Weisman GA.

Trends Pharmacol Sci. 1994 Aug;15(8):280-1. No abstract available.

PMID:
7802838
43.

Stimulation of phospholipase C in cultured microvascular endothelial cells from human frontal lobe by histamine, endothelin and purinoceptor agonists.

Purkiss JR, West D, Wilkes LC, Scott C, Yarrow P, Wilkinson GF, Boarder MR.

Br J Pharmacol. 1994 Apr;111(4):1041-6.

45.

A role for phospholipase D in control of mitogenesis.

Boarder MR.

Trends Pharmacol Sci. 1994 Feb;15(2):57-62. Review.

PMID:
8165726
46.
47.

Phospholipase D activation regulates endothelin-1 stimulation of phosphoinositide-specific phospholipase C in SK-N-MC cells.

Challiss RA, Wilkes LC, Patel V, Purkiss JR, Boarder MR.

FEBS Lett. 1993 Jul 26;327(2):157-60.

49.

Phospholipase D in chromaffin cells?

Boarder MR.

J Neurochem. 1993 May;60(5):1978-80. No abstract available.

PMID:
8473914
50.

Supplemental Content

Loading ...
Support Center